STAAR Surgical Company (STAA) Stock Score, Valuation & Financial Research
STAAR Surgical Company is in the Healthcare sector and Medical - Instruments & Supplies industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 30/100.
Quick answer for STAA
STAAR Surgical Company currently has a Wall Street Score of 30/100. The stored market price is $22.66. Its financial score is 43/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What STAAR Surgical Company does
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of health
STAA financial snapshot
- Wall Street Score:
- 30/100
- Current price:
- $22.66
- Market capitalization:
- $1.13B
- Revenue:
- $290.4M
- Net income:
- $-21.0M
- Free cash flow:
- $-40.0M
- Cash:
- $131.9M
- Total debt:
- $37.3M
- EPS:
- -1.62
- Financial score:
- 43/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-40.0M, showing cash burn in the current stored period.
- The balance sheet shows $131.9M of cash versus $37.3M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 43/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research STAA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.